CAR T cell therapy is driving better cancer treatment outcomes

by | Feb 9, 2021

Tags: Biotech | CHM | PTX

StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses cancer treatment through the use of CAR T cell therapy.

Populating the expert panel this week is Jennifer Chow, COO of Chimeric Therapeutics (ASX:CHM) and Steven Yatomi-Clarke CEO, Prescient Therapeutics (ASX:PTX).

Chimeric grabbed headlines in January 2021, following news it easily achieved its IPO fundraising target of $35m.

Prescient also featured in a recent Stockhead article looking at its choice of three cancer programs for its next-generation CAR T platform.

The group discusses a range of topics, including how both companies began developing CAR T cell therapies, the tumour types being targeted, timescales towards strong revenue, research plans for the year ahead and much more.



Submit a Comment

Your email address will not be published. Required fields are marked *